Bright Minds Biosciences (DRUG) Assets Average (2021 - 2026)

Bright Minds Biosciences' Assets Average history runs 6 years deep, the most recent figure standing at $146.5 million for Q1 2026.

• Quarterly Assets Average rose 260.95% year-over-year to $146.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.5 million (up 260.95% YoY) and the FY2025 annual result came in at $32.9 million, up 585.16% from the prior year.
• Assets Average was $146.5 million for Q1 2026 at Bright Minds Biosciences, up from $63.3 million in the prior quarter.
• Across five years, Assets Average topped out at $146.5 million in Q1 2026 and bottomed at $4.5 million in Q3 2024.
• A 5-year average of $25.7 million and a median of $8.1 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average tumbled 52.39% — and 2025, when it jumped 994.67%.
• Bright Minds Biosciences' Assets Average stood at $8.9 million in 2022, then slumped by 42.68% to $5.1 million in 2023, then jumped by 354.16% to $23.1 million in 2024, then surged by 173.37% to $63.3 million in 2025, then jumped by 131.56% to $146.5 million in 2026.
• Business Quant data shows DRUG's Assets Average at $146.5 million in Q1 2026, $63.3 million in Q4 2025, and $49.6 million in Q3 2025.